BioPharmSignal logoBioPharmSignal

Biotech News

RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th

RenovoRx (RNXT)RenovoRxPartnership

RNXT (RNXT) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is rnxt.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

RNXTRenovoRx2026-08-04 12:30 EST

RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th

RNXTRenovoRx2026-08-21 12:30 EST

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

BMYBMYBristol-Myers Squibb Company2026-07-20 10:59 EST

Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA

MGNXMacroGenics2026-08-11 20:05 EST

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

NRIXNurix Therapeutics2026-07-21 20:01 EST

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

IDYAIDEAYA Biosciences2026-08-19 10:00 EST

IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer

RVMDRevolution Medicines2026-08-10 10:01 EST

Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration

CHRSCoherus BioSciences, Inc.2026-06-23 18:00 EST

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

GSKGSK plc2026-07-21 10:28 EST

ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026

View all latest news

RenovoRx

Targeted Intra-Arterial Drug Delivery RenovoRx develops a localized drug-delivery approach intended to concentrate therapy within solid tumors while reducing systemic exposure. Its Trans-Arterial Micro-Perfusion platform combines a device with a targeted treatment protocol. RenovoCath RenovoCath is an FDA-cleared dual-balloon infusion...

Recent company news

RNXTRenovoRx2026-08-21 12:30 EST

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

RNXTRenovoRx2026-08-20 12:30 EST

RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment

RNXTRenovoRx2026-08-12 20:05 EST

RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

RNXTRenovoRx2026-08-11 12:30 EST

RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

RNXTRenovoRx2026-08-06 12:30 EST

RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

Stock data

Close
1.32 USD
Market cap
41.06M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States